Article
Immunology
Chia-Ping Su, K. Arnold Chan, Ching-Tai Huang, Chi-Tai Fang
Summary: The study shows that inhaled zanamivir is as effective as oral oseltamivir in preventing influenza-related hospitalization or death for outpatients.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
Sofia Tejada, Miia Jansson, Candela Sole-Lleonart, Jordi Rello
Summary: Neuraminidase inhibitors (NAIs) therapy significantly reduced the time to clinical resolution, total influenza-related complications, acute otitis media and need for antibiotic treatment. While reductions in mortality, pneumonia, asthma exacerbations, and hospitalization rates only demonstrated a trend benefit with NAIs treatment. The most significant adverse event associated with NAIs was an increase in nausea and vomiting.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2021)
Review
Medicine, General & Internal
Jen-Wei Liu, Shen-Hua Lin, Lin-Chien Wang, Hsiao-Yean Chiu, Jen-Ai Lee
Summary: This study compared the efficacy and safety of neuraminidase inhibitors and the endonuclease inhibitor for the treatment of seasonal influenza among healthy adults and children. The results showed that zanamivir was associated with the shortest time to alleviation of influenza symptoms, while baloxavir was associated with reduced rate of influenza-related complications.
Article
Pharmacology & Pharmacy
Andrei A. Ivashchenko, Jeremy C. Jones, Dmitry O. Shkil, Yan A. Ivanenkov, Philippe Noriel Q. Pascua, Melissa K. Penaflor, Ruben N. Karapetian, Elena A. Govorkova, Alexandre V. Ivachtchenko
Summary: In this study, the efficacy of a new orally-dosed neuraminidase inhibitor (NAI) AV5080 against different subtypes of influenza viruses was examined. AV5080 showed superior in vitro efficacy compared to currently approved NAIs, oseltamivir and zanamivir. However, it exhibited reduced inhibition against certain viral variants, such as NA-E119G and NA-R292K. These findings suggest that AV5080 is a promising orally-dosed NAI.
ANTIVIRAL RESEARCH
(2023)
Article
Virology
Phillip J. Yates, Nalini Mehta, Helen A. Watson, Amanda F. Peppercorn
Summary: Influenza infection can be serious and even fatal, but antiviral medications like neuraminidase inhibitors are important for the treatment of severely ill patients. However, the development of resistance can make these drugs less effective. A study using Next Generation Sequencing found previously undetectable resistance mutations in respiratory samples of patients being treated with IV zanamivir. However, the clinical significance of these mutations is unclear.
Article
Infectious Diseases
Deepali Kumar, Michael G. Ison, Jean-Paul Mira, Tobias Welte, Jick Hwan Ha, David S. Hui, Nanshan Zhong, Takefumi Saito, Laurie Katugampola, Neil Collinson, Sarah Williams, Steffen Wildum, Andrew Ackrill, Barry Clinch, Nelson Lee
Summary: This study tested the combination of baloxavir with NAIs in hospitalized patients with severe influenza but found no superior clinical outcomes compared to NAIs alone. The combination was well tolerated, suggesting that combination antivirals may not be routinely indicated in clinical practice for this patient population.
LANCET INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Najat Bdeir, Prerna Arora, Sabine Gaertner, Stefan Poehlmann, Michael Winkler
Summary: The presence of multiple DI RNAs derived from genomic segments encoding polymerase subunits might not result in increased antiviral activity, showing no significant impact on viral replication and interferon induction.
SCIENTIFIC REPORTS
(2021)
Article
Virology
Rubaiyea Farrukee, Vithiagaran Gunalan, Sebastian Maurer-Stroh, Patrick C. Reading, Aeron C. Hurt
Summary: This study aims to predict permissive mutations that may enable the emergence of a fit H275Y A(H1N1)pdm09 variant. Computational analysis and experimental approaches identified potential permissive mutations and evaluated their fitness impact. The study provides valuable insights into the evolutionary pathways of oseltamivir resistance in influenza viruses.
JOURNAL OF VIROLOGY
(2022)
Article
Environmental Sciences
Magdalena Swierczynska, Dagmara M. Mirowska-Guzel, Edyta Pindelska
Summary: This article presents the possibilities of using all available antiviral drugs specific for influenza A and B, and compares the currently recommended anti-influenza medications. It highlights the promising new drug baloxavir marboxil, and suggests further research on combination therapy.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Article
Pharmacology & Pharmacy
Sofia Tejada, Alexandre M. Tejo, Yolanda Pena-Lopez, Carlos G. Forero, Xavier Corbella, Jordi Rello
Summary: The study found that baloxavir and neuraminidase inhibitors (NAIs) have a significant reduction effect on complications of uncomplicated influenza, especially in reducing antibiotic prescriptions. Single-dose baloxavir is non-inferior to NAIs in terms of safety and efficacy.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2021)
Article
Biology
Min Li, Guang-chao Han, Yang Chen, Wen-xiu Du, Fang Liu, Yu-min Chi, Jun-feng Du
Summary: In patients with COPD, oseltamivir and zanamivir both effectively reduced body temperature, but oseltamivir showed better improvement in influenza-like symptoms.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
(2021)
Article
Multidisciplinary Sciences
Hiroshige Mikamo, Yusuke Koizumi, Yuka Yamagishi, Nobuhiro Asai, Yuko Miyazono, Toshikazu Shinbo, Michiko Horie, Kenichi Togashi, Elissa M. Robbins, Nobuo Hirotsu
Summary: This study compared the performance of the Liat test on the cobas Liat system with RADTs in diagnosing influenza. The results showed that the Liat test had higher sensitivity and specificity in the early stages of infection, making it more effective for diagnosing influenza in children and adults.
Article
Medicine, General & Internal
Agustin Pijierro Amador, Alba Suarez Cordero, Pedro Sanchez Risco
Summary: A 40-year-old man presented with symptoms of acute intermittent porphyria (AIP), including abdominal pain and inappropriate behaviour. After treatment, the patient initially improved but experienced a relapse after starting oseltamivir treatment for a flu-like illness. The patient's condition improved again after discontinuing the treatment.
Article
Microbiology
Renee W. Y. Chan, Kin P. Tao, Jiqing Ye, Kevin K. Y. Lui, Xiao Yang, Cong Ma, Paul K. S. Chan
Summary: Influenza virus is a major public health challenge characterized by high morbidity and mortality. Oseltamivir is commonly used as an antiviral, but resistant strains have been detected. This study designed and synthesized two new compounds that showed significant antiviral activity against both seasonal and oseltamivir-resistant strains. These compounds have the potential to be an important addition to the arsenal of antiviral drugs.
Article
Immunology
Xin Liu, Thomas Balligand, Claire Carpenet, Hidde L. Ploegh
Summary: The immune system protects the body by eliminating pathogens such as viruses and bacteria. Researchers have developed a conjugate that combines the influenza neuraminidase inhibitor zanamivir with a nanobody that recognizes mouse immunoglobulin. This conjugate targets virus-infected cells and stimulates the immune system to eliminate them. It has shown effective prophylactic and therapeutic effects against influenza.
SCIENCE IMMUNOLOGY
(2023)